Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Fig. 3

Baseline serum cytokine levels and clinical response at Week 24 in participants with TNFi-IR PsA from COSMOS by ACR20 response or IGA 0/1 response and change from baseline in serum IL-6 level by ACR20 or IGA 0/1 response over time. (A) Baseline serum levels of IL-22 and IFNγ levels by ACR20 response at Week 24; (B) Baseline serum levels of SAA, IFNγ, IL-17A, and IL-6 by IGA 0/1 response at Week 24; (C) Change from baseline in IL-6 levels by ACR20 and IGA 0/1 responses through Week 24. *p < 0.05 between responders and nonresponders. ACR20,  ≥ 20% improvement in American College of Rheumatology response criteria; GUS, guselkumab; IFN, interferon; IGA 0/1 response, Investigator’s Global Assessment score of 0 or 1 with at least a 2-point improvement from baseline; IL, interleukin; PBO, placebo; PsA, psoriatic arthritis; Q8W, every 8 weeks; SAA, serum amyloid A; TNFi-IR, tumor necrosis factor inhibitor-inadequate response

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us